Innovation Platform Technology Needs March 2014 Al Lauritano Director, Technology Licensing and Collaboration al_lauritano@bd.com Glenn Vonk Director, Advanced Technology glenn_vonk@bd.com
Global & Growing Medical (4.3) Diagnostics (2.6) Biosciences 30,000 Associates in 50 Countries (1.1) 58% Ex-US Revenues (8.1 $B Revenues, 2013) +5.4%
Securing Technology: PLAIID Strategy • BD Medical (MS) BD Diabetes Care NGOs BD Medical Surgical Systems Partner BD Pharm Systems Corporations • BD Diagnostics (BDD) License BD Diagnostic Systems Foundations BD PreAnalytical Systems BD Womens Health Acquire .gov • BD Biosciences (BDB) Start-Ups BD Adv. Bioprocessing Invest BD Cell Analysis Universities • Information Business Unit (IBU) Incubate • Global Health Angels • BD TBD Develop Incubators Open Innovation Collaborate and Develop Commercialize
BD IncuLink™ Global Acceleration Funding Partner Angels, VCs, Grant Agency Corporate Immediate Benefits: • Expand Opportunity Pool • Leverage Risk • Expand Partner Pool BD Mentoring & In-kind (HC, $$$, Services) Technology Partner Infrastructure Partner Inventor, University, Accelerators, Incubators Entrepreneur, NewCo Clusters
BD Technologies: Corporate Technology Wants Information Enabled Medical Devices and Big Data Analytics Technologies that identify, locate and communicate device or patient status to distributed systems. Flexible and scalable architectures with analytics and decision support to enable dynamic care paradigms or satisfy regulatory needs. App human factors and healthcare social networking. Parenteral Delivery Materials, coatings, and adhesives that reduce inflammation or infection to enhance biocompatibility for extended-use parenteral delivery devices. Predictive models that speed preclinical testing decreasing both time & risk of translational clinical studies. Microfluidics Systems for preparing and stabilizing well-characterized plasma, cell and particle populations, nucleic acids, and proteins from whole human blood which minimize risk of infection or contamination. Methods to stabilize different blood components for downstream analytics. Technologies to cost-effectively link these devices to information systems which reliably identify providers and patients. Next Generation Sequencing Specimen preparation and bioinformatic technologies to enable personalized medicine. Corporate V Metagenomic (microbiome) applications, esp. diagnostics. Developing World / Maternal and Neonatal Health Easy to use technologies with significant potential to improve outcomes at an affordable cost.
BD Business Units Technology Wants Connected Devices Cost-effective, compact, connected, disposable electromechanical devices for acquiring tissues, managing chronic conditions, or administering drugs. Ability to interact with patients, providers, and other assets to minimize infections, needlesticks, exposure hazards, and other adverse events. Devices to enhance patient access and comfort by assisting with routine or complex tasks. Sustainable materials and processes. Specimen Collection and Preservation Cost effective, safe, easy-to-use sample preparation and stabilization. Systems to extract nucleic acids from diverse tissues and or paraffin blocks. Closed, disposable devices to isolate, enrich, or safely preserve rare or single cells from diverse tissues to maximize viability and therapeutic effect. Systems to rapidly separate, mix, and meter human plasma. Automation Automation to improve healthcare efficiency and effectiveness – esp. for nurses, pharmacies, human sample preparation or preservation, and flow cytometry. Diagnostics Probes and dyes offering exceptionally sensitive, robust detection in processed human specimens. Methods for sequencing individual rare cells. Differentiated Point-of-Care diagnostic systems. Non-invasive diagnostics. Analytics Analytics supporting connected BD devices, systems, and their users to improve effectiveness, efficiency, and outcomes. 6
Recommend
More recommend
